Aug. 13, 2015
Exosect Ltd., a leading provider of enabling technologies, has announced that its Chief Technology Officer, Dr. Aoife Dillon, presented data at the International Congress on Invertebrate Pathology and Microbial Control, which demonstrates the ability of Entostat to enable alternative application methods for the delivery of biological active ingredients.
Conidia of Beauveria bassiana adhering to a spherical particle of Entostat - Copyright Exosect Ltd.
At the University of British Columbia in Vancouver, the presentation focussed on the use of the Entostat platform as a delivery mechanism for an isolate of Beauveria bassiana in two formulations.
Beauveria bassiana is an entomopathogenic fungus that grows naturally in soils throughout the world. It is unusual in that it offers dual control against both insects and plant pathogens and is also used as an animal feed additive.
Entostat, a patented electrostatic micro-powder, delivers biological active ingredients. In both formulations of Exosect's isolate of Beauveria bassiana, Entostat optimises the delivery of fungal spores enabling application to building structures (demonstrated in grain stores) for the first formulation and delivery of fungal spores as an admixture to grain for the second formulation.
A dossier for approval of the microbial pest control active (B.bassiana isolate) is currently under EU review by the Rapporteur Member State and this will be followed by draft Registration Report (dRR) submissions in 2016 for both the structural and admix formulations. Exosect are currently seeking partners, both within the EU and US for the development and commercialisation of both formulations.